![](https://endpts.com/wp-content/uploads/2023/11/Steve-Butts-ArrivoBio-CEO.jpg)
Steve Butts, Arrivo BioVentures CEO
Arrivo bags $45M Series B to fund major depression late-stage test and PhII-ready pancreatitis asset
Arrivo BioVentures has closed an oversubscribed $45.25 million Series B fundraise with an eye to progress its pipeline through the next stage of trials, including …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.